Navigation Links
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Date:5/15/2008

Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile,

with Low Incidence of Grade 3 and 4 Neuropathy

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

"The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy," said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. "The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine."

About Study 211

Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients receiv
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
2. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
3. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... available in its catalogue: ... for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... and Company) (NYSE: BDX ), a leading global ... the top 25 companies in Newsweek,s second annual ... environmental performance, policies and reputation. BD ranked 24th overall and ... also received a 2010 Green Power Leadership Award from the ...
... Calif., Oct. 25 Questcor Pharmaceuticals, Inc. (Nasdaq: ... at the 21st Annual Oppenheimer Healthcare Conference at 1:00 p.m. ... in New York. Don M. Bailey, President and Chief Executive ... developments. Attendance at this conference is by invitation ...
Cached Medicine Technology:BD Ranks Among Top 25 U.S. Companies in Newsweek's 2010 Green Rankings; Receives EPA Green Power Leadership Award; Named to Dow Jones Sustainability World Index for Fifth Consecutive Year 2BD Ranks Among Top 25 U.S. Companies in Newsweek's 2010 Green Rankings; Receives EPA Green Power Leadership Award; Named to Dow Jones Sustainability World Index for Fifth Consecutive Year 3
(Date:4/23/2014)... Washington, April 21, 2014 Five for-profit and ... of $1.25 million in Proof of Concept grants ... ideas into commercial products, the Life Sciences Discovery ... $300,000 Entrepreneur Mentoring Program grant to the Washington ... statewide advisory network to train the next generation ...
(Date:4/23/2014)... Leisure Time Physical Activity on Mobility Limitation in Old ... the risk of mobility limitation in old age, whereas ... in a study which followed up 5,200 public sector ... the Gerontology Research Center in Finland and the Finnish ... often repetitive, wears the body and lasts for several ...
(Date:4/23/2014)... shown that proliferation of endogenous neural precursor cells ... and axons. From the perspective of neural plasticity, ... University in China observed the effects of functional ... proliferation and expression of basic fibroblast growth factor ... on the infarct side. The researchers found that ...
(Date:4/22/2014)... leaders visited the New Jersey Institute of Technology ... Bloom for the launch of the New Jersey ... a new model for business innovation through the ... and investment. U.S. Senator Cory Booker, Panasonic Corp. ... New Jersey Lieutenant Governor Kim Guadagno, New Jersey ...
(Date:4/22/2014)... clinics that can provide primary care for low-income ... hospitals and insurance companies while improving patient health, ... admissions suggests that health clinics that avoid costs ... money by lowering hospital admission rates and emergency ... economics, Penn State Altoona. , The researchers ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2
... InterComponentWare Appoints Chief Medical Officer, WAYNE, ... urologist and,medical informatics expert, has been appointed ... global leader in eHealth networking and,communications solutions., ... Joining InterComponentWare in 2006, Dr. Feinen initially ...
... Summit, WASHINGTON, June 19 The Fourth National,Summit ... Westin Washington,D.C., City Center from June 20-22. Secretary of ... will help ensure that women veterans,know about the benefits ... women than ever serving in our armed forces, this ...
... begin practicing at Reproductive Science Center July 14, ... New England has expanded its physician staff with the ... also,accomplished in adult stem cell research and implantation biology. ... Milford, Westborough and,Lexington, Mass., "We are proud to ...
... researchers and five Boston-area community groups received a National ... effects of pollution exposure in neighborhoods adjacent to major ... Institute of Environmental Health Science (NIEHS) will fund ... Somerville, MA. , A steering committee comprised ...
... key to Blue companies, stewardship of,healthcare dollars, ... companies, anti-fraud investigations resulted in overall savings and,recoveries ... to data released,by the Blue Cross and Blue ... for all Blue Cross and Blue Shield companies, ...
... Pennsylvania-Grown Tomatoes, HARRISBURG, Pa., June 19 ... among Pennsylvania,residents, State Health Secretary Dr. Calvin B. ... current multi-state Salmonella outbreak,associated with tomatoes that has ... case each has been identified in Bucks, Butler, ...
Cached Medicine News:Health News:Dr. Rainer Feinen to Fill New Post 2Health News:VA Reaches Out to Women Veterans 2Health News:Leading Fertility Center Adds New Physician 2Health News:NIH funds highway pollution and health study in Boston, Somerville 2Health News:Blue Cross and Blue Shield Companies' Anti-Fraud Units Recover and Save More Than $249 Million In 2007 2Health News:Blue Cross and Blue Shield Companies' Anti-Fraud Units Recover and Save More Than $249 Million In 2007 3Health News:Pennsylvania Department of Health Investigates Salmonella Cases Linked to National Outbreak 2
The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
... is a compact, stand-alone microprocessor-controlled photometer designed ... 96-well microplates using single- or dual- wavelength ... and a dynamic reading range up to ... any laboratory or assay requirements. Self-diagnostics (up ...
... System is made up of three integral ... and the Merci Balloon Guide Catheter. The ... location of the clot has been identified ... is inserted through a small incision in ...
A 3080/3085 orthopedic extension serves as a mobile, radiolucent orthopedic platform. When not in use, accessories can be removed and stored in cart....
Medicine Products: